NCT05901259 The EXOPULSE Study - a Database for Routine Follow-up of Clinical Outcomes
| NCT ID | NCT05901259 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Exoneural Network AB |
| Condition | Cerebral Palsy |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2026-02-18 |
| Primary Completion | 2027-08-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2026-02-18 with a primary completion date of 2027-08-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objective is to explore the potential short and long-term impact of the EXOPULSE Mollii Suit and EXOPULSE Suit on subjects with CP, MS, stroke, fibromyalgia or other neurologic disorders which may cause such types of symptoms, and to identify high responders among the sub-categories of the diagnoses. The primary endpoint will be improvements in the Berg/Pediatric Balance Scale (BBS/PBS) as a measurement of balance and risk of falls.
Eligibility Criteria
Inclusion Criteria: * Diagnosed with CP, MS, stroke, fibromyalgia or other neurologic disorder that may cause such type of symptoms. * Diagnosed \>6 months prior to inclusion in case of MS or stroke as well as \>1 month prior to inclusion in the case of fibromyalgia. * Give written informed consent * Cognitively able to understand and follow verbal and/or written instructions * A minimum age of 2 years Exclusion Criteria: * Any of the contraindications listed in the instructions for use of the EXOPULSE Mollii Suit or EXOPULSE Suit * Being introduced to any new medication affecting the neuromuscular activity during the study period * Using botulinum toxin \<3 month before or during the study period * Subjects \<100 cm and \<13 kg * Subjects \>205 cm and \>115 kg
Contact & Investigator
Milana Mileusnic, PhD
PRINCIPAL INVESTIGATOR
Otto Bock Healthcare Products GmbH
Frequently Asked Questions
Who can join the NCT05901259 clinical trial?
This trial is open to participants of all sexes, aged 2 Years or older, studying Cerebral Palsy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05901259 currently recruiting?
Yes, NCT05901259 is actively recruiting participants. Contact the research team at milana.mileusnic@ottobock.com for enrollment information.
Where is the NCT05901259 trial being conducted?
This trial is being conducted at Bergshamra, Sweden.
Who is sponsoring the NCT05901259 clinical trial?
NCT05901259 is sponsored by Exoneural Network AB. The principal investigator is Milana Mileusnic, PhD at Otto Bock Healthcare Products GmbH. The trial plans to enroll 200 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.